Cargando…
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs
In this new era of highly effective oral antiviral drugs for chronic hepatitis C virus (HCV), indications for antiviral treatment may be extendable. This study undertaken to identify suitable candidates for peg-interferon plus ribavirin (PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma...
Autores principales: | Lee, Seung Ho, Jin, Young-Joo, Shin, Jun Young, Lee, Jin-Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228644/ https://www.ncbi.nlm.nih.gov/pubmed/28072684 http://dx.doi.org/10.1097/MD.0000000000005321 |
Ejemplares similares
-
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
Publicado: (2017) -
Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs: Erratum
Publicado: (2017) -
Survival benefit of radiofrequency ablation for solitary (3–5 cm) hepatocellular carcinoma: An analysis for nationwide cancer registry
por: Lee, Seung Ho, et al.
Publicado: (2017) -
Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study
por: Liu, Zhenhua, et al.
Publicado: (2023) -
Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study
por: Yeh, Ming-Lun, et al.
Publicado: (2015)